

	AVASTIN	LUCENTIS	EYLEA	Brolucizumab
Q3 2011	63%	37%	0%	
Q1 2012	57%	32%	11%	
Q2	58%	28%	14%	
Q3	53%	27%	20%	
Q4	48%	30%	21%	
Q1 2013	46%	30%	24%	
Q2	48%	29%	23%	
Q3	46%	27%	26%	
Q4	48%	26%	25%	
Q1 2014	49%	25%	25%	
Q2	48%	26%	26%	
Q3	47%	26%	27%	
Q4	44%	26%	30%	
Q1 2015	46%	22%	32%	
Q2	45%	24%	31%	
Q3	43%	26%	32%	
Q4	45%	22%	34%	
Q1 2016	47%	19%	35%	
Q2	46%	19%	35%	
Q3	45%	19%	34%	
Q4	43%	22%	35%	
Q1 2017	46%	19%	35%	
Q2	43%	18%	39%	
Q3	44%	18%	38%	
Q4	46%	17%	37%	
Q1 2018	43%	20%	37%	
Q2	40%	19%	41%	
Q3	43%	19%	38%	
Q4	40%	19%	41%	
Q1 2019	41%	18%	41%	
Q2	41%	19%	40%	
Q3	40%	17%	43%	
Q4	45%	13%	39%	3%
Q1 2020	43%	13%	39%	5%
Q2	39%	15%	41%	5%
Q3	43%	14%	39%	4%
Q4	41%	14%	40%	5%
Q2 2021	39%	14%	44%	3%

Mylan v. Regeneron
IPR2021-00881
U.S. Pat. 9,254,338
Exhibit 2280